SHANGHAI, July 31, 2026
IMPACT Therapeutics announced an exclusive licensing agreement with Pharmanovia, granting the global specialty pharmaceutical company exclusive rights to manufacture, develop, and commercialize senaparib across Europe, the Middle East and North Africa (MENA), Australia, and New Zealand. The agreement covers maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Under the deal, IMPACT Therapeutics is eligible to receive up to €423.5 million through an upfront payment, regulatory milestones, commercial milestone payments tied to sales thresholds, and tiered royalties reaching the mid-twenties percent on net product sales. The partnership expands senaparib’s global commercial footprint to 66 countries, representing the company’s first major commercialization agreement outside China as it advances its international oncology strategy.
Strategic Partnership Accelerates Global Commercial Expansion
The licensing agreement provides Pharmanovia with exclusive rights across 66 markets, including all 27 European Union member states, the United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Australia, New Zealand, and countries throughout the Middle East and North Africa. IMPACT Therapeutics stated that the collaboration leverages Pharmanovia’s established regulatory, commercial, and distribution infrastructure to accelerate patient access following regulatory approvals. The company’s Marketing Authorisation Application (MAA) for senaparib as a first-line maintenance therapy for advanced ovarian cancer was formally accepted by the European Medicines Agency (EMA) in August 2025, with regulatory approval anticipated during the second half of 2026. The partnership is expected to strengthen IMPACT’s global brand recognition while supporting broader commercialization of its precision oncology portfolio beyond the Chinese market.
Senaparib Expands Global Presence Following China Approval
Senaparib (IMP4297) is a next-generation PARP1/2 inhibitor independently developed by IMPACT Therapeutics for the treatment of ovarian and other solid tumors. The therapy received approval from China’s National Medical Products Administration (NMPA) in January 2025 as a first-line maintenance treatment for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieved complete or partial response following platinum-based chemotherapy. It was subsequently included in China’s National Reimbursement Drug List (NRDL) in December 2025, expanding patient access nationwide. According to the company, senaparib’s unique molecular design delivers high target selectivity and a broad safety window while supporting ongoing development across additional indications and combination treatment strategies as part of its lifecycle management program.
Advertisement
Agreement Strengthens IMPACT’s Precision Oncology Strategy
The collaboration represents a significant milestone in IMPACT Therapeutics’ global commercialization strategy, reinforcing its position as a developer of synthetic lethality-based precision cancer therapies. Beyond senaparib, the company’s oncology pipeline includes PARP1-selective inhibitors, ATR inhibitors, WEE1 inhibitors, and multiple investigational targeted therapies designed to address unmet needs in cancer treatment. By partnering with Pharmanovia, IMPACT aims to accelerate international regulatory approvals, expand patient access to innovative oncology medicines, and strengthen long-term commercial growth across key global markets. The agreement also highlights increasing international interest in China’s biotechnology innovation and underscores the growing role of strategic licensing partnerships in bringing novel precision oncology treatments to patients worldwide.
Source: IMPACT Therapeutics,press release
